Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285 is registered in ClinicalTrials.gov with Jon Simmons as lead sponsor.

NCT NCT04445285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04445285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Lead sponsor
Jon Simmons
Phase
Phase 2
Overall status
Recruiting
Start date
April 28, 2020
Completion date
February 28, 2022
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19